On October 13, the list of Tianjin's first batch of gazelle enterprises (Gazelle enterprises refer to high-tech high-growth enterprises with leaping development trend supported by technological innovation or business model innovation.) in 2022 was announced. With its technological innovation and R&D achievements in the field of chronic disease management, Minkang stood out among a number of enterprises and was highly recognized by relevant government departments.

After more than ten years of development, Minkang has formed four leading domestic technical systems of electrochemistry, photochemistry, colloidal gold and immunofluorescence, and has obtained more than 50 patents and software copyrights. The whole series of products cover the detection of blood glucose, blood lipids, blood ketone, uric acid, glycosylated hemoglobin, and rapidly upgrade according to the development path of blood glucose detection - multiple indicators detection - intelligent detection, to create an ecological closed-loop of chronic disease management from monitoring to data analysis to implementation of diagnosis and treatment programs.